search
Back to results

Melatonin Supports Non Surgical Periodontal Treatment in Patients With Type 2 Diabetes and Periodontitis

Primary Purpose

Diabetes Mellitus, Periodontitis, Melatonin

Status
Completed
Phase
Phase 4
Locations
Turkey
Study Type
Interventional
Intervention
Melatonin 3 MG
Sponsored by
Yağmur Saraç Gül
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Diabetes Mellitus

Eligibility Criteria

31 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: According to the WHO, in individuals in the young age category (18-65 years) Periodontitis diagnosed patients, "stage 3/4 periodontitis" was determined according to the current periodontal disease and condition classification as the diagnostic criterion for periodontitis Diabetic patients, our diagnostic criteria for Type 2 DM was fasting plasma glucose level greater than 126 mg/dl and glycosylated hemoglobin level (HbA1c) greater than 6.5%. Exclusion Criteria: Smoke, use antibiotics, anti-inflammatory and antioxidant drugs in the last 6 months Work night shifts Pregnancy and lactation Cancer and autoimmune diseases Kidney disease Periodontal treatment in the last 6 months Obese patients (In Europe, obesity is defined as a body-mass index of more than 30 kg/m2 and a waist circumference of more than 88 cm in women and 102 cm in men)

Sites / Locations

  • Yagmur Sarac Gul

Arms of the Study

Arm 1

Arm 2

Arm Type

No Intervention

Active Comparator

Arm Label

fmSRP

fmSRP-mel

Arm Description

27 patients with diabetic periodontitis underwent full mouth scaling and root planning (fmSRP) alone

28 patients with diabetic periodontitis were administered systemic melatonin tablets (6 mg daily, for 30 days) immediately after fmSRP.

Outcomes

Primary Outcome Measures

Clinical Findings: Plaque index score(PI)
According to the tooth Plaque index, each tooth surface was divided into 4 separate regions and the plaque intensity for each region is scored as: 0 = No plaque in the gingival area. = A film of plaque adhering to the free gingival margin and adjacent area of the tooth. The plaque may only be recognized by running a probe across the tooth surface. = Moderate accumulation of soft deposits within the gingival pocket, on the gingival margin and/or adjacent tooth surface, which can be seen by the naked eye. = Abundance of soft matter within the gingival pocket and/or on the gingival margin and adjacent tooth surface. Finally, scores are collected and calculate the arithmetic mean for the mouth score.
Clinical Findings: Gingival index score (GI)
The criteria are entirely confined to qualitative changes in the gingival soft tissue.Periodontal probe was used and gently inserted the sulcus. Each tooth surface was divided into 4 separate regions and the gingival bleeding activity for each region is scored as: 0 = Normal gingiva = Mild inflammation -slight change in color, slight oedema. No bleeding on probing = Moderate inflammation-redness, oedema and glazing. Bleeding on probing =Severe inflammation -marked redness and oedema. Ulceration. Tendency to spontaneous bleeding. Finally, scores are collected and calculate the arithmetic mean for the mouth score.
Clinical Findings: Bleeding on probing(BOP)
Each tooth surface was divided into 4 separate regions and gently probed by using periodontal probe.There is a bleeding as a positive score, and there is no bleeding as a negative score. The BOP is considered positive if bleeding occurred between 30 seconds after probing. Whole the probed area and positive score area ratio were calculated and BOP(%)score was found.
Clinical Findings:Probing pocket depth (PPD)
Probing pocket depth (PPD) measured with a periodontal probe on 6 different points around each tooth. PPD is known as distance between gingival margin and the base of the pocket/sulcus. By using periodontal probe(Williams periodontal probe) 6 different points are measured. Each scores of surfaces are collected and averaged for the mouth score for PPD.
Clinical Findings: Clinical Attachment Level (CAL)
By using periodontal probe(Williams periodontal probe) 6 different points are measured.CAL, distance from the bottom of the pocket to the cemento-enamel junction of tooth. If there is gingival recession, recession depth is also added the CAL. By using periodontal probe(Williams periodontal probe) 6 different points are measured. Each scores of surfaces are collected and averaged for the mouth score for CAL.
Biochemical Findings: RANKL (pg/ml)
RANKL (pg/ml) were measured samples from gingival crevicular fluid by using commercial ELİSA kits according to the instructions of the kit manufacturer
Biochemical Findings: OPG (pg/ml)
OPG (pg/ml) were measured samples from gingival crevicular fluid by using commercial ELİSA kits according to the instructions of the kit manufacturer
Biochemical Findings: MMP-8(ng/ml)
MMP-8(ng/ml) were measured samples from gingival crevicular fluid by using commercial ELİSA kits according to the instructions of the kit manufacturer
Biochemical Findings: IL-beta(pg/ml)
IL-beta(pg/ml) were measured samples from serum by using commercial ELİSA kits according to the instructions of the kit manufacturer
Biochemical Findings: RANKL/OPG
RANKL/OPG, numeric ratio that can be indicated as only numeric value(no need some kind of units)

Secondary Outcome Measures

Full Information

First Posted
March 25, 2023
Last Updated
May 18, 2023
Sponsor
Yağmur Saraç Gül
search

1. Study Identification

Unique Protocol Identification Number
NCT05870358
Brief Title
Melatonin Supports Non Surgical Periodontal Treatment in Patients With Type 2 Diabetes and Periodontitis
Official Title
Melatonin Supports Non Surgical Periodontal Treatment in Patients With Type 2 Diabetes and Periodontitis
Study Type
Interventional

2. Study Status

Record Verification Date
May 2023
Overall Recruitment Status
Completed
Study Start Date
February 18, 2021 (Actual)
Primary Completion Date
January 18, 2022 (Actual)
Study Completion Date
June 18, 2022 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Yağmur Saraç Gül

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Background and aim: Hyperinflammatory host response associated with diabetes mellitus significantly provokes periodontal tissue destruction. In this context, supporting the standard treatment of periodontitis in diabetics with host modulation agents is a current field of study. This clinical study aims to investigate the clinical efficacy of melatonin supplementation in non-surgical periodontal treatment in patients with Type 2 DM and periodontitis and its biological basis (clinical effectiveness) based on some basic markers. Material and method: In this randomized controlled and double-blind study, 27 of 55 patients with diabetic periodontitis underwent full mouth scaling and root planning (fmSRP) alone and 28 of them were administered melatonin (6 mg daily, for 30 days) in addition to fmSRP. The possible therapeutic contribution of melatonin was evaluated clinically and biochemically [gingival crevicular fluid (GCF) RANKL, OPG and MMP-8 and serum IL-1β levels] at 3 and 6 months.
Detailed Description
Ethical Approval This double-blind and randomized controlled clinical study was carried out on 55 patients with Type 2 DM and periodontitis who applied to the Periodontology Clinic of the Faculty of Dentistry of Recep Tayyip Erdoğan University between 2021/February and 2022/January and met the study criteria. Ethical approval was given by the Clinical Research Ethics Committee of the Faculty of Medicine of the same university within the framework of the Declaration of Helsinki (2008) (2022/03). The possible risks and benefits of the treatment to be applied to the participants were mentioned and their verbal and written consents were obtained. Working Groups According to the WHO, in individuals in the young age category, "stage 3/4 periodontitis" was determined according to the current periodontal disease and condition classification as the diagnostic criterion for periodontitis. Accordingly, probing pocket depth (PPD) should be at least 6mm and bone loss should be at least 3mm. Our diagnostic criteria for Type 2 DM was fasting plasma glucose (FPG) level greater than 126 mg/dl and glycosylated hemoglobin level (HbA1c) greater than 6.5%. Those who smoke, use antibiotics, anti-inflammatory and antioxidant drugs in the last 6 months, work night shifts, are in pregnancy and lactation, have cancer and autoimmune diseases, have kidney disease, have received any periodontal treatment in the last 6 months obese patients were also excluded from the study. In Europe, obesity is defined as a body-mass index (BMI) of more than 30 kg/m2 and a waist circumference of more than 88 cm in women and 102 cm in men. Treatment Protocol According to the above criteria, patients included in the study were randomly divided into control (fmSRP) and treatment [fmSRP-melatonin (fmSRP-mel)] groups by a computer program by an independent researcher (HA). The investigator (YSG), who provided the sample and conducted the clinical procedures, was blind to the study groups. fmSRP is the approach of completing supragingival and subgingival debridement procedures within 24 hours with periodontal curettes, scalers and ultrasonic instruments. Additional melatonin administration was made in the form of tablets containing 6mg of melatonin daily for 30 days from the day following the SRP. Patients were instructed to take the tablets just before bedtime. No additional application was made in the control group. Within the scope of the non-surgical periodontal treatment program, all patients were trained on brushing teeth with the modified bass technique and the use of appropriate interface cleaning tools. These trainings were repeated in the maintenance sessions. Participants were also instructed not to use any mouthwash. Sample Collection and Clinical Periodontal Measurements Clinical periodontal measurements with gingival crevicular fluid(GCF) and serum samples were performed at baseline (T0) and at 3th (T1) and 6th months (T2) following fmSRP. In all three periods, sampling was done one day before clinical periodontal measurements. GCF samples were taken from the interproximal regions of the two teeth with the most radiographic bone loss in each of the four quadrants in the morning. Initially, proper isolation was achieved by means of cotton rolls. The area was slightly dried for 10 seconds. Sterile paper strips (Periopaper, Proflow, Inc., Amityviile, NY) were advanced until minimal resistance was felt in the sulcus. Waited 30 seconds. Paper strips contaminated with blood or saliva were not included. The GCF volume in each paper strip was measured using the periotron device (Periotron 8010 Harco Electronics, Winnipeg, Canada) by electrical compedance method and recorded as µl. Immediately afterwards, 8 paper strips obtained from each patient were transferred to an eppendorf tube containing 250 µl of phosphate buffer solution. It was stored in a -80°C freezer (Thermo Fisher Scientific, Waltham, MA, USA) until the day of biochemical analysis. Immediately following the GCF samples, 16 cc venous blood samples were taken from the left arm antecubital fossa region of the patients. After the blood was centrifuged at 3000 rpm at 2-8oC for 15 minutes, serum samples were obtained (Elektro-mag, Istanbul, Turkey). The samples were taken into Eppendorf tubes and kept in a -80°C freezer (Thermo Fisher Scientific, Waltham, MA, USA) until the day of analysis. Plaque index (PI), gingival index (GI), bleeding on probing (BOP), PPD and clinical attachment level (CAL) measurements were performed for clinical periodontal status assessments. PPD was measured as the distance between the deepest point of the sulcus and the gingival margin, and CAL as the distance between the deepest point of the sulcus and the enamel-cementum junction. Scoring for each tooth was made from 6 different regions for PPD and CAL, and from 4 different regions for other indices. Williams periodontal probe (Hu-Friedy, Chicago, IL, USA) was used for measurements. Biochemical Analysis Eppendorf tubes, which were removed from the freezer 24 hours before the experiment, were allowed to thaw gradually, first at -20oC and then at +4oC. The samples and reagents were brought to room temperature (18-25oC) just before the analysis. RANKL (Catalog no: E-EL-H5813), OPG (Catalog no: E-EL-H1341) and MMP-8 (Catalog no: E-EL-H1450) analyzes in GCF samples, IL-1ß (Catalog no: E- EL-H0149) analyzes were performed on serum samples using the enzyme-linked immunosorbent assay (ELISA) method and according to the instructions of the kit manufacturer (Elabscience, Houston, Texas, USA). Results were calculated as ng/ml (MMP-8) and pg/ml (IL-1β, RANKL and OPG). Statistical Analysis Windows 17.0 for SPSS program was used for statistical analysis. (SPSS Inc., Chicago, USA) The conformity of the data to the normal distribution was evaluated with the Shapiro Wilk test. The Mann Whitney U test was used for intergroup comparisons, and the Friedman, Wilxocon tests and Bonferroni correction were used for the analysis of time-dependent within-group changes. Chi-square test was applied for comparison between groups in terms of genders. A p<0.05 level was considered statistically significant.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus, Periodontitis, Melatonin, Matrix Metalloproteinases

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
55 (Actual)

8. Arms, Groups, and Interventions

Arm Title
fmSRP
Arm Type
No Intervention
Arm Description
27 patients with diabetic periodontitis underwent full mouth scaling and root planning (fmSRP) alone
Arm Title
fmSRP-mel
Arm Type
Active Comparator
Arm Description
28 patients with diabetic periodontitis were administered systemic melatonin tablets (6 mg daily, for 30 days) immediately after fmSRP.
Intervention Type
Drug
Intervention Name(s)
Melatonin 3 MG
Other Intervention Name(s)
Melatonina 3mg
Intervention Description
In this clinical trial, all patients that have both diabetes mellitus and periodontitis were performed full mouth scaling and root planning in order to start their periodontal treatments. Different from the control group, in fmSRP-mel group's patients systemic melatonin tablets (6 mg daily, for 30 days) were given immediately after the fmSRP procedure in order to support the scaling and root planning.
Primary Outcome Measure Information:
Title
Clinical Findings: Plaque index score(PI)
Description
According to the tooth Plaque index, each tooth surface was divided into 4 separate regions and the plaque intensity for each region is scored as: 0 = No plaque in the gingival area. = A film of plaque adhering to the free gingival margin and adjacent area of the tooth. The plaque may only be recognized by running a probe across the tooth surface. = Moderate accumulation of soft deposits within the gingival pocket, on the gingival margin and/or adjacent tooth surface, which can be seen by the naked eye. = Abundance of soft matter within the gingival pocket and/or on the gingival margin and adjacent tooth surface. Finally, scores are collected and calculate the arithmetic mean for the mouth score.
Time Frame
Change from baseline(T0) to 3rd month(T1) and 6th month(T2)
Title
Clinical Findings: Gingival index score (GI)
Description
The criteria are entirely confined to qualitative changes in the gingival soft tissue.Periodontal probe was used and gently inserted the sulcus. Each tooth surface was divided into 4 separate regions and the gingival bleeding activity for each region is scored as: 0 = Normal gingiva = Mild inflammation -slight change in color, slight oedema. No bleeding on probing = Moderate inflammation-redness, oedema and glazing. Bleeding on probing =Severe inflammation -marked redness and oedema. Ulceration. Tendency to spontaneous bleeding. Finally, scores are collected and calculate the arithmetic mean for the mouth score.
Time Frame
Change from baseline(T0) to 3rd month(T1) and 6th month(T2)
Title
Clinical Findings: Bleeding on probing(BOP)
Description
Each tooth surface was divided into 4 separate regions and gently probed by using periodontal probe.There is a bleeding as a positive score, and there is no bleeding as a negative score. The BOP is considered positive if bleeding occurred between 30 seconds after probing. Whole the probed area and positive score area ratio were calculated and BOP(%)score was found.
Time Frame
Change from baseline(T0) to 3rd month(T1) and 6th month(T2)
Title
Clinical Findings:Probing pocket depth (PPD)
Description
Probing pocket depth (PPD) measured with a periodontal probe on 6 different points around each tooth. PPD is known as distance between gingival margin and the base of the pocket/sulcus. By using periodontal probe(Williams periodontal probe) 6 different points are measured. Each scores of surfaces are collected and averaged for the mouth score for PPD.
Time Frame
Change from baseline(T0) to 3rd month (T1) and 6th month (T2)
Title
Clinical Findings: Clinical Attachment Level (CAL)
Description
By using periodontal probe(Williams periodontal probe) 6 different points are measured.CAL, distance from the bottom of the pocket to the cemento-enamel junction of tooth. If there is gingival recession, recession depth is also added the CAL. By using periodontal probe(Williams periodontal probe) 6 different points are measured. Each scores of surfaces are collected and averaged for the mouth score for CAL.
Time Frame
Change from baseline(T0) to 3rd month(T1) and 6th month(T2)
Title
Biochemical Findings: RANKL (pg/ml)
Description
RANKL (pg/ml) were measured samples from gingival crevicular fluid by using commercial ELİSA kits according to the instructions of the kit manufacturer
Time Frame
Change from baseline(T0) to 3rd month(T1) and 6th month(T2)
Title
Biochemical Findings: OPG (pg/ml)
Description
OPG (pg/ml) were measured samples from gingival crevicular fluid by using commercial ELİSA kits according to the instructions of the kit manufacturer
Time Frame
Change from baseline(T0) to 3rd month(T1) and 6th month(T2)
Title
Biochemical Findings: MMP-8(ng/ml)
Description
MMP-8(ng/ml) were measured samples from gingival crevicular fluid by using commercial ELİSA kits according to the instructions of the kit manufacturer
Time Frame
Change from baseline(T0) to 3rd month(T1) and 6th month(T2)
Title
Biochemical Findings: IL-beta(pg/ml)
Description
IL-beta(pg/ml) were measured samples from serum by using commercial ELİSA kits according to the instructions of the kit manufacturer
Time Frame
Change from baseline(T0) to 3rd month(T1) and 6th month(T2)
Title
Biochemical Findings: RANKL/OPG
Description
RANKL/OPG, numeric ratio that can be indicated as only numeric value(no need some kind of units)
Time Frame
Change from baseline(T0) to 3rd month(T1) and 6th month(T2)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
31 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: According to the WHO, in individuals in the young age category (18-65 years) Periodontitis diagnosed patients, "stage 3/4 periodontitis" was determined according to the current periodontal disease and condition classification as the diagnostic criterion for periodontitis Diabetic patients, our diagnostic criteria for Type 2 DM was fasting plasma glucose level greater than 126 mg/dl and glycosylated hemoglobin level (HbA1c) greater than 6.5%. Exclusion Criteria: Smoke, use antibiotics, anti-inflammatory and antioxidant drugs in the last 6 months Work night shifts Pregnancy and lactation Cancer and autoimmune diseases Kidney disease Periodontal treatment in the last 6 months Obese patients (In Europe, obesity is defined as a body-mass index of more than 30 kg/m2 and a waist circumference of more than 88 cm in women and 102 cm in men)
Facility Information:
Facility Name
Yagmur Sarac Gul
City
Rize
ZIP/Postal Code
53020
Country
Turkey

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Melatonin Supports Non Surgical Periodontal Treatment in Patients With Type 2 Diabetes and Periodontitis

We'll reach out to this number within 24 hrs